Abstract:Background: Alzheimer's disease, a lethal neurodegenerative disorder that leads to progressive memory loss, is the most common form of dementia. Owing to the complexity of the disease, its root cause still remains unclear. The existing anti-Alzheimer's drugs are unable to cure the disease while the current therapeutic options have provided only limited help in restoring moderate memory and remain ineffective at restricting the disease's progression. The striatal-enriched protein tyrosine phosphatase (STEP) has been shown to be involved in the internalization of the receptor, N-methyl D-aspartate (NMDR) and thus is associated with the disease. The present study was performed using machine learning algorithms, docking protocol and molecular dynamics (MD) simulations to develop STEP inhibitors, which could be novel anti-Alzheimer's molecules. Methods: The present study deals with the generation of computational predictive models based on chemical descriptors of compounds using machine learning approaches followed by substructure fragment analysis. To perform this analysis, the 2D molecular descriptors were generated and machine learning algorithms (Naïve Bayes, Random Forest and Sequential Minimization Optimization) were utilized. The binding mechanisms and the molecular interactions between the predicted active compounds and the target protein were modelled using docking methods. Further, the stability of the protein-ligand complex was evaluated using MD simulation studies. The substructure fragment analysis was performed using Substructure fingerprint (SubFp), which was further explored using a predefined dictionary. Results: The present study demonstrates that the computational methodology used can be employed to examine the biological activities of small molecules and prioritize them for experimental screening. Large unscreened chemical libraries can be screened to identify potential novel hits and accelerate the drug discovery process. Additionally, the chemical libraries can be searched for significant substructure patterns as reported in the present study, thus possibly contributing to the activity of these molecules.

Investigating Targets for Neuropharmacological Intervention by Molecular Dynamics Simulations

Molecular dynamics simulations and novel drug discovery

In Silico Identification of Multi-Target Ligands as Promising Hit Compounds for Neurodegenerative Diseases Drug Development

Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development

A Survey on Computational Methods in Drug Discovery for Neurodegenerative Diseases

Network-Based Target Prioritization and Drug Candidate Identification for Multiple Sclerosis: from Analyzing "omics Data" to Druggability Simulations.

Empirical Analysis of Drug Targets for Nervous System Disorders

Steered Molecular Dynamics Simulation in Rational Drug Design

Molecular Hybridization as a Tool in the Design of Multi-target Directed Drug Candidates for Neurodegenerative Diseases

Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers

Checking the STEP-Associated Trafficking and Internalization of Glutamate Receptors for Reduced Cognitive Deficits: A Machine Learning Approach-Based Cheminformatics Study and Its Application for Drug Repurposing

Discerning of isatin-based monoamine oxidase (MAO) inhibitors for neurodegenerative disorders by exploiting 2D, 3D-QSAR modelling and molecular dynamics simulation

An Overview of Aflat Neurological Diseases and Drug Discovery: An Overview

A Combined Computational and Experimental Approach to Studying Tropomyosin Kinase Receptor B Binders for Potential Treatment of Neurodegenerative Diseases

Integrated Molecular Modeling and Machine Learning for Drug Design

Use of quantitative clinical pharmacology to improve early clinical development success in neurodegenerative diseases

Drug design benefits from molecular dynamics: some examples.

Multi-objective generative AI for designing novel brain-targeting small molecules

Thermodynamics and Kinetics of Drug-Target Binding by Molecular Simulation

Evaluation Framework for AI-driven Molecular Design of Multi-target Drugs: Brain Diseases as a Case Study

Current Small Molecules‐Based Medicinal Chemistry Approaches for Neurodegeneration Therapeutics